Ticker Symbol | Entity Name | As Of Date | Company Name | Followers | Employees on Linkedin | Link | Industry | Date Added | Date Updated | Description | Website | Specialities | Logo | HQ.Street | HQ.City | HQ.State | HQ.Country | HQ.Postal | Headcount change in past 24 months | Company Name | Sector | Industry |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
private:anaphore | 296210 | May 22nd, 2019 12:00AM | Anaphore, Inc. | 132 | 1.00 | Open | Research | May 22nd, 2019 12:05AM | May 22nd, 2019 12:05AM | Anaphore is pioneering Atrimer™ therapeutics —a new class of protein pharmaceuticals that promise to surpass the therapeutic reach of today’s biologics. The company uses its proprietary Atrimer technology platform to rapidly identify and program trivalent proteins that can block or activate virtually any target in disease pathways. Though focusing on oncology and immunology, Anaphore is committed to collaborating with partners across the spectrum of therapeutic indications. | Open | Open | 10931 N Torrey Pines Rd Ste 101 | La Jolla | CA | US | 92037 | Anaphore | ||||
private:anaphore | 296210 | Mar 19th, 2018 12:00AM | Anaphore, Inc. | 133 | 1.00 | Open | Research | Mar 18th, 2018 11:48PM | Mar 18th, 2018 11:48PM | Open | Anaphore | |||||||||||
private:anaphore | 296210 | Feb 17th, 2018 12:00AM | Anaphore, Inc. | 133 | 1.00 | Open | Research | Feb 17th, 2018 02:25PM | Feb 17th, 2018 02:25PM | Anaphore is pioneering Atrimer™ therapeutics —a new class of protein pharmaceuticals that promise to surpass the therapeutic reach of today’s biologics. The company uses its proprietary Atrimer technology platform to rapidly identify and program trivalent proteins that can block or activate virtually any target in disease pathways. Though focusing on oncology and immunology, Anaphore is committed to collaborating with partners across the spectrum of therapeutic indications. | Anaphore | |||||||||||
private:anaphore | 296210 | Feb 16th, 2018 12:00AM | Anaphore, Inc. | 133 | 1.00 | Open | Research | Feb 16th, 2017 08:15AM | Feb 16th, 2017 08:15AM | Anaphore is pioneering Atrimer™ therapeutics —a new class of protein pharmaceuticals that promise to surpass the therapeutic reach of today’s biologics. The company uses its proprietary Atrimer technology platform to rapidly identify and program trivalent proteins that can block or activate virtually any target in disease pathways. Though focusing on oncology and immunology, Anaphore is committed to collaborating with partners across the spectrum of therapeutic indications. | Anaphore | |||||||||||
private:anaphore | 296210 | Feb 15th, 2018 12:00AM | Anaphore, Inc. | 133 | 1.00 | Open | Research | Feb 15th, 2017 10:07AM | Feb 15th, 2017 10:07AM | Anaphore is pioneering Atrimer™ therapeutics —a new class of protein pharmaceuticals that promise to surpass the therapeutic reach of today’s biologics. The company uses its proprietary Atrimer technology platform to rapidly identify and program trivalent proteins that can block or activate virtually any target in disease pathways. Though focusing on oncology and immunology, Anaphore is committed to collaborating with partners across the spectrum of therapeutic indications. | Anaphore | |||||||||||
private:anaphore | 296210 | Feb 14th, 2018 12:00AM | Anaphore, Inc. | 133 | 1.00 | Open | Research | Feb 14th, 2017 01:50PM | Feb 14th, 2017 01:50PM | Anaphore is pioneering Atrimer™ therapeutics —a new class of protein pharmaceuticals that promise to surpass the therapeutic reach of today’s biologics. The company uses its proprietary Atrimer technology platform to rapidly identify and program trivalent proteins that can block or activate virtually any target in disease pathways. Though focusing on oncology and immunology, Anaphore is committed to collaborating with partners across the spectrum of therapeutic indications. | Anaphore | |||||||||||
private:anaphore | 296210 | Feb 13th, 2018 12:00AM | Anaphore, Inc. | 133 | 1.00 | Open | Research | Feb 13th, 2017 04:11PM | Feb 13th, 2017 04:11PM | Anaphore is pioneering Atrimer™ therapeutics —a new class of protein pharmaceuticals that promise to surpass the therapeutic reach of today’s biologics. The company uses its proprietary Atrimer technology platform to rapidly identify and program trivalent proteins that can block or activate virtually any target in disease pathways. Though focusing on oncology and immunology, Anaphore is committed to collaborating with partners across the spectrum of therapeutic indications. | Anaphore | |||||||||||
private:anaphore | 296210 | Feb 12th, 2018 12:00AM | Anaphore, Inc. | 133 | 1.00 | Open | Research | Feb 12th, 2017 04:15AM | Feb 12th, 2017 04:15AM | Anaphore is pioneering Atrimer™ therapeutics —a new class of protein pharmaceuticals that promise to surpass the therapeutic reach of today’s biologics. The company uses its proprietary Atrimer technology platform to rapidly identify and program trivalent proteins that can block or activate virtually any target in disease pathways. Though focusing on oncology and immunology, Anaphore is committed to collaborating with partners across the spectrum of therapeutic indications. | Anaphore | |||||||||||
private:anaphore | 296210 | Feb 11th, 2018 12:00AM | Anaphore, Inc. | 133 | 1.00 | Open | Research | Feb 11th, 2017 05:35AM | Feb 11th, 2017 05:35AM | Anaphore is pioneering Atrimer™ therapeutics —a new class of protein pharmaceuticals that promise to surpass the therapeutic reach of today’s biologics. The company uses its proprietary Atrimer technology platform to rapidly identify and program trivalent proteins that can block or activate virtually any target in disease pathways. Though focusing on oncology and immunology, Anaphore is committed to collaborating with partners across the spectrum of therapeutic indications. | Anaphore | |||||||||||
private:anaphore | 296210 | Feb 10th, 2018 12:00AM | Anaphore, Inc. | 133 | 1.00 | Open | Research | Feb 10th, 2017 06:43AM | Feb 10th, 2017 06:43AM | Anaphore is pioneering Atrimer™ therapeutics —a new class of protein pharmaceuticals that promise to surpass the therapeutic reach of today’s biologics. The company uses its proprietary Atrimer technology platform to rapidly identify and program trivalent proteins that can block or activate virtually any target in disease pathways. Though focusing on oncology and immunology, Anaphore is committed to collaborating with partners across the spectrum of therapeutic indications. | Anaphore |